Skip to main content

AN2 Therapeutics, Inc.

corporate_fare Company Profile

AN2 Therapeutics, Inc.

ANTX·NASDAQ·Life Sciences·CIK 0001880438

AN2 Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops new small-molecule therapeutics using its boron chemistry platform. The company's development pipeline includes programs in hematologic diseases, infectious diseases, and oncology. AN2 Therapeutics has three Phase 2 studies anticipated to begin in 2026, two preclinical candidates, and advanced research programs targeting oncology, bone disorders, and infectious diseases. One key product in development is epetraborole, which is being expanded into a Phase 2 proof-of-concept clinical study for adults with phlebotomy-dependent polycythemia vera (PV). PV is a blood cancer where the bone marrow overproduces red blood cells, increasing hematocrit and potentially leading to serious complications like arterial and venous thromboembolic events. Approximately 155,000 people in the U.S. are estimated to be affected by PV. AN2 Therapeutics plans to initiate the Phase 2 trial for epetraborole in India in the third quarter of 2026. This study is expected to include an open-label sentinel cohort, an open-label dose optimization cohort (Part 1), a double-blind, randomized, placebo-controlled cohort (Part 2), and an optional open-label extension cohort (Part 3).

AN2 Therapeutics, Inc. (NASDAQ:ANTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ANTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for ANTX spans 10-Q, 8-K, DEF 14A, 424B3.

Recent high-impact activity:

  • AN2 10-Q: Q3 Loss Narrows to $8.0M, $80.2M Cash, Material Weaknesses Persist
  • FDA Clears IND for Oral Epetraborole Phase 2 in Polycythemia Vera; Trial Starts Q4
  • AN2 Therapeutics Q2 Loss Widens to $8.2M on Higher R&D; Cash Runway into 2029
  • AN2 Therapeutics Flags Ongoing Internal Control Weaknesses
  • AN2 Therapeutics Reports Q2 2026 Results, Extends Cash Runway into 2029, and Plans Three Phase 2 Programs by Year-End

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$35.17M
Diluted EPS
-$1.16
Op. Cash Flow
-$29.83M
Operating Income
-$38.11M
Cash & Equivalents
$19.94M
Debt / Equity
0.00×
Shares Outstanding
27.41M sh
Source: 10-K · filed 2026-03-17 · accession 0001193125-26-110693

Short Interest & Short Volume

9.18 days to cover

FINRA reported short interest of 2,440,372 shares in ANTX as of the October 30, 2026 settlement, a 15.5% decrease from the prior period — about 9.2 days to cover at its recent average daily volume. On November 20, 2026, 70.4% of ANTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,440,372 shares as of October 30, 2026
Change vs prior period▼ 15.5%
Days to cover9.18 at avg daily volume of 265,757
Daily short volume (FINRA facilities)70.4% of 133,307 shares on November 20, 2026
5-day average short volume64.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$5.08
52-week range · as of 2026-11-09 $1 – $7.19
Market cap
$192.75M
Volume
332.7K (1.1× avg)
3-mo avg 315.5K
Live data · 2026-11-21 14:45 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ANTX - Latest Insights

ANTX
Nov 09, 2026, 7:33 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.00
Real-time Price: $5.08 info
Change: +$1.08 (+27%) info
Market Cap: $192.754M info
ANTX
Nov 02, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $4.54
Real-time Price: $5.08 info
Change: +$0.540 (+12%) info
Market Cap: $192.754M info
ANTX
Aug 11, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.87
Real-time Price: $5.08 info
Change: -$0.790 (-13%) info
Market Cap: $192.754M info
ANTX
Aug 11, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.87
Real-time Price: $5.08 info
Change: -$0.790 (-13%) info
Market Cap: $192.754M info
ANTX
Aug 11, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.87
Real-time Price: $5.08 info
Change: -$0.790 (-13%) info
Market Cap: $192.754M info
ANTX
Jun 04, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.17
Real-time Price: $5.08 info
Change: +$0.910 (+22%) info
Market Cap: $192.754M info
ANTX
Jun 04, 2026, 7:08 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.32
Real-time Price: $5.08 info
Change: +$0.760 (+18%) info
Market Cap: $192.754M info
ANTX
May 11, 2026, 4:08 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.78
Real-time Price: $5.08 info
Change: +$0.2976 (+6%) info
Market Cap: $192.754M info
ANTX
May 11, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.78
Real-time Price: $5.08 info
Change: +$0.2976 (+6%) info
Market Cap: $192.754M info
ANTX
May 11, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.78
Real-time Price: $5.08 info
Change: +$0.2976 (+6%) info
Market Cap: $192.754M info
ANTX
Apr 22, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $5.08 info
Change: +$1.08 (+27%) info
Market Cap: $192.754M info
ANTX
Apr 20, 2026, 4:33 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $3.55
Real-time Price: $5.08 info
Change: +$1.53 (+43%) info
Market Cap: $192.754M info
ANTX
Apr 20, 2026, 4:32 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.55
Real-time Price: $5.08 info
Change: +$1.53 (+43%) info
Market Cap: $192.754M info
ANTX
Apr 09, 2026, 5:21 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $3.07
Real-time Price: $5.08 info
Change: +$2.01 (+65%) info
Market Cap: $192.754M info
ANTX
Apr 09, 2026, 5:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.07
Real-time Price: $5.08 info
Change: +$2.01 (+65%) info
Market Cap: $192.754M info
ANTX
Mar 20, 2026, 4:37 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.91
Real-time Price: $5.08 info
Change: +$1.17 (+30%) info
Market Cap: $192.754M info
ANTX
Mar 17, 2026, 4:03 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $5.02
Real-time Price: $5.08 info
Change: +$0.060 (+1%) info
Market Cap: $192.754M info
ANTX
Mar 17, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.02
Real-time Price: $5.08 info
Change: +$0.0632 (+1%) info
Market Cap: $192.754M info
ANTX
Mar 09, 2026, 9:43 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.92
Real-time Price: $5.08 info
Change: +$0.160 (+3%) info
Market Cap: $192.754M info
ANTX
Mar 03, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.13
Real-time Price: $5.08 info
Change: +$3.95 (+350%) info
Market Cap: $192.754M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets